A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Exercise Mimetics: SLU-PP-332 and 5-Amino-1MQ

SLU-PP-332 and 5-amino-1MQ are preclinical research compounds with no published human trials and no approved use. Both are sold online as research chemicals and marketed as exercise mimetics, but the evidence is limited to cell and mouse studies. They are small molecules, not peptides, and WADA S0 applies. Vegalab does not make, sell or source them.

SLU-PP-332

SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERR alpha, beta and gamma), nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism in muscle. In mice, it increased oxidative muscle fiber gene programs and running endurance, and in obese mice it reduced fat mass and improved insulin sensitivity. It was developed at academic laboratories as a tool compound; no human pharmacokinetic or safety data are published. Its name derives from Saint Louis University, where it was developed.

5-Amino-1MQ

5-amino-1-methylquinolinium is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and is highly expressed in adipose tissue. NNMT inhibition raises intracellular NAD+ and SAM in adipocytes. In diet-induced obese mice, 5-amino-1MQ reduced body weight and white adipose mass. No human studies are published. NNMT has also been studied as a biomarker in metabolic and cancer research. Inhibitors vary widely in selectivity, and the long-term consequences of blocking this methylation pathway, which also affects nicotinamide clearance and methyl donor balance, are not established in any species beyond short mouse studies.

Regulatory status

Neither compound is approved as a drug or allowed as a dietary supplement ingredient. Both lack any approval for human therapeutic use, so they fall under WADA S0, and ERR or AMPK-pathway agents may also fall under S4 metabolic modulators. Products sold online have no quality assurance. Anti-doping laboratories monitor novel compounds marketed to athletes, and detection methods are developed as they appear. Unregulated online products may also contain undeclared substances. Clinicians should treat any reported use as exposure to an uncharacterized chemical.

Delivery facts

SLU-PP-332 is a lipophilic small molecule with limited reported oral pharmacokinetics; mouse studies mainly used injection. 5-amino-1MQ is a permanently charged quaternary cation, which limits passive membrane permeation. Both would need full preclinical PK and toxicology before any human formulation work. Formulation work on unapproved compounds without toxicology would be premature. The appropriate sequence is preclinical characterization first, then delivery design. Vegalab does not undertake it for these compounds, and they are described here only as delivery case studies.

Key facts

SLU-PP-332, a synthetic ERR agonist, reduced fat mass and improved insulin sensitivity in obese mice (Billon et al. 2024, J Pharmacol Exp Ther 388:232)
Small-molecule NNMT inhibitors including 5-amino-1MQ reversed diet-induced obesity in mice (Neelakantan et al. 2018, Biochem Pharmacol 147:141)
Non-approved substances are prohibited at all times under S0 (WADA Prohibited List 2026)

How our delivery technology applies

These compounds illustrate two opposite delivery problems: a lipophilic small molecule that needs solubilization, and a permanently charged cation that cannot cross membranes passively. Multi-layer encapsulation addresses the first with a lipid core and the second only partially, through mucoadhesion and permeation enhancement. Neither is a product candidate for Vegalab; they are included as delivery case studies for partners with a regulated pathway.

Have a preclinical small molecule with a solubility problem? Talk to our feasibility team.